Loading…

Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain

Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of actio...

Full description

Saved in:
Bibliographic Details
Published in:Human psychopharmacology 2008-06, Vol.23 (4), p.275-281
Main Authors: Karagianis, Jamie, Hoffmann, Vicki Poole, Arranz, Belen, Treuer, Tamás, Maguire, Gerald A., de Haan, Lieuwe, Chawla, Bharat
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3
cites cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3
container_end_page 281
container_issue 4
container_start_page 275
container_title Human psychopharmacology
container_volume 23
creator Karagianis, Jamie
Hoffmann, Vicki Poole
Arranz, Belen
Treuer, Tamás
Maguire, Gerald A.
de Haan, Lieuwe
Chawla, Bharat
description Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/hup.933
format article
fullrecord <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_hup_933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_SBPPQW0B_M</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgiptT_AbSmwep5k-bpEcV3QR1ExUvQkibt120y0pSmfPTW-nQk6f3hefHc3gQOiT4lGBMz-YfzWnG2BYaEpxlMcFCbKMhljKNOaV0gPZCeMO4y3C2iwZEMiYTyofodep1Xa8jY4N1LVRet9ZV0bLW7ks31kGknYmaZQuutbruXFmCB1dAiKyLWg-6XXRZDAvwVfdEK7DVvI0qbd0-2il1HeBgc0fo-frq6XIS307HN5fnt3HBUsZikwgAnvM8NyQtkjShEguZizKlRvBEclZoQVPCCce0MKWkkHFCuZG6oIYWbISO-97CL0PwUKrG24X2a0Ww-tlHdfuobp9OHvWy-cgXYP7cZpAOnPRgZWtY_9ejJs-zvi7utQ0tfP5q7d8VF0yk6uV-rB4vZrOHF3yh7tg3KYZ_OQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><source>Wiley</source><creator>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</creator><creatorcontrib>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</creatorcontrib><description>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.933</identifier><identifier>PMID: 18338426</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Administration, Oral ; Antipsychotic Agents - administration &amp; dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; atypical antipsychotic ; Benzodiazepines - administration &amp; dosage ; Benzodiazepines - adverse effects ; Benzodiazepines - therapeutic use ; disintegrating ; dissolving ; Drug Delivery Systems ; Humans ; olanzapine ; Patient Compliance ; Schizophrenia - drug therapy ; Solubility ; Tablets ; weight ; Weight Gain - drug effects</subject><ispartof>Human psychopharmacology, 2008-06, Vol.23 (4), p.275-281</ispartof><rights>Copyright © 2008 John Wiley &amp; Sons, Ltd.</rights><rights>(c) 2008 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</citedby><cites>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18338426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karagianis, Jamie</creatorcontrib><creatorcontrib>Hoffmann, Vicki Poole</creatorcontrib><creatorcontrib>Arranz, Belen</creatorcontrib><creatorcontrib>Treuer, Tamás</creatorcontrib><creatorcontrib>Maguire, Gerald A.</creatorcontrib><creatorcontrib>de Haan, Lieuwe</creatorcontrib><creatorcontrib>Chawla, Bharat</creatorcontrib><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><title>Human psychopharmacology</title><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><description>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><subject>Administration, Oral</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>atypical antipsychotic</subject><subject>Benzodiazepines - administration &amp; dosage</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - therapeutic use</subject><subject>disintegrating</subject><subject>dissolving</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>olanzapine</subject><subject>Patient Compliance</subject><subject>Schizophrenia - drug therapy</subject><subject>Solubility</subject><subject>Tablets</subject><subject>weight</subject><subject>Weight Gain - drug effects</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp10E9LwzAYBvAgiptT_AbSmwep5k-bpEcV3QR1ExUvQkibt120y0pSmfPTW-nQk6f3hefHc3gQOiT4lGBMz-YfzWnG2BYaEpxlMcFCbKMhljKNOaV0gPZCeMO4y3C2iwZEMiYTyofodep1Xa8jY4N1LVRet9ZV0bLW7ks31kGknYmaZQuutbruXFmCB1dAiKyLWg-6XXRZDAvwVfdEK7DVvI0qbd0-2il1HeBgc0fo-frq6XIS307HN5fnt3HBUsZikwgAnvM8NyQtkjShEguZizKlRvBEclZoQVPCCce0MKWkkHFCuZG6oIYWbISO-97CL0PwUKrG24X2a0Ww-tlHdfuobp9OHvWy-cgXYP7cZpAOnPRgZWtY_9ejJs-zvi7utQ0tfP5q7d8VF0yk6uV-rB4vZrOHF3yh7tg3KYZ_OQ</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Karagianis, Jamie</creator><creator>Hoffmann, Vicki Poole</creator><creator>Arranz, Belen</creator><creator>Treuer, Tamás</creator><creator>Maguire, Gerald A.</creator><creator>de Haan, Lieuwe</creator><creator>Chawla, Bharat</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200806</creationdate><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><author>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Oral</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>atypical antipsychotic</topic><topic>Benzodiazepines - administration &amp; dosage</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - therapeutic use</topic><topic>disintegrating</topic><topic>dissolving</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>olanzapine</topic><topic>Patient Compliance</topic><topic>Schizophrenia - drug therapy</topic><topic>Solubility</topic><topic>Tablets</topic><topic>weight</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karagianis, Jamie</creatorcontrib><creatorcontrib>Hoffmann, Vicki Poole</creatorcontrib><creatorcontrib>Arranz, Belen</creatorcontrib><creatorcontrib>Treuer, Tamás</creatorcontrib><creatorcontrib>Maguire, Gerald A.</creatorcontrib><creatorcontrib>de Haan, Lieuwe</creatorcontrib><creatorcontrib>Chawla, Bharat</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karagianis, Jamie</au><au>Hoffmann, Vicki Poole</au><au>Arranz, Belen</au><au>Treuer, Tamás</au><au>Maguire, Gerald A.</au><au>de Haan, Lieuwe</au><au>Chawla, Bharat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><date>2008-06</date><risdate>2008</risdate><volume>23</volume><issue>4</issue><spage>275</spage><epage>281</epage><pages>275-281</pages><issn>0885-6222</issn><eissn>1099-1077</eissn><abstract>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>18338426</pmid><doi>10.1002/hup.933</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0885-6222
ispartof Human psychopharmacology, 2008-06, Vol.23 (4), p.275-281
issn 0885-6222
1099-1077
language eng
recordid cdi_crossref_primary_10_1002_hup_933
source Wiley
subjects Administration, Oral
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
atypical antipsychotic
Benzodiazepines - administration & dosage
Benzodiazepines - adverse effects
Benzodiazepines - therapeutic use
disintegrating
dissolving
Drug Delivery Systems
Humans
olanzapine
Patient Compliance
Schizophrenia - drug therapy
Solubility
Tablets
weight
Weight Gain - drug effects
title Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T02%3A57%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orally%20disintegrating%20olanzapine%20and%20potential%20differences%20in%20treatment-emergent%20weight%20gain&rft.jtitle=Human%20psychopharmacology&rft.au=Karagianis,%20Jamie&rft.date=2008-06&rft.volume=23&rft.issue=4&rft.spage=275&rft.epage=281&rft.pages=275-281&rft.issn=0885-6222&rft.eissn=1099-1077&rft_id=info:doi/10.1002/hup.933&rft_dat=%3Cistex_cross%3Eark_67375_WNG_SBPPQW0B_M%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18338426&rfr_iscdi=true